Skip to main content
Caplight Logo









Via Nova Therapeutics

Via Nova Therapeutics

Private
Oakland, CaliforniaHealthcare & Life Scienceshttps://www.vianovatx.com/

Last Round

Series A

Sep 7, 2021

Total Funding Raised

$20M

Company Overview

Via Nova Therapeutics is a biotechnology company that develops innovative antiviral therapeutics for acute and subacute viral infections, specifically targeting respiratory viruses and their replication mechanisms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antiviral drug discoverysmall-molecule therapeuticsbiotech startuppreclinical developmentviral disease treatmentdrug pipelinebiopharmastructure-based drug designphenotypic screeninginvestigational new drugINDdrug discovery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Via Nova Therapeutics Comparables

Compare Via Nova Therapeutics with similar companies based on industry and business-model similarity.

Via Nova Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Eradivir
85%
Selva Therapeutics
81%
Orthogon Therapeutics
80%

Via Nova Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 7, 2021

Via Nova Therapeutics Investors

Notable investors and investment history

Via Nova Therapeutics investors
InvestorRounds
Aditum BioSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 7, 2021

    $20M round led by Aditum Bio

Via Nova Therapeutics Filings

Explore SEC and related filing metadata, where available.

Via Nova Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Via Nova Therapeutics's valuation, stock price, and market status.

Is Via Nova Therapeutics a public or private company?

Via Nova Therapeutics is a private company.

What is the current stock price of Via Nova Therapeutics?

Via Nova Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Via Nova Therapeutics worth (valuation)?

Valuation information for Via Nova Therapeutics is not publicly available.

Can I buy Via Nova Therapeutics stock?

Via Nova Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Via Nova Therapeutics's last funding round?

Via Nova Therapeutics's most recent funding round was Series A on September 7, 2021.

Who are the main investors in Via Nova Therapeutics?

Key investors in Via Nova Therapeutics include Aditum Bio.

Will Via Nova Therapeutics IPO soon?

No public IPO plans have been announced for Via Nova Therapeutics.

How can I track Via Nova Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Via Nova Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOakland, California
Employee Range1
Year Founded2021
Last FundingSep 7, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?